The Global Alzheimer’s Drugs Market, by Drug (Donepezil, Rivastigmine, Galantamine and Memantine) by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and e-Commerce) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 7 billion in 2016 and is projected to exhibit a CAGR of 9.5% over the forecast period (2017 – 2025). The Alzheimer’s drugs market is expected to gain significant traction with the increasing innovations in development of novel drugs by the manufacturers and increased government funding for research on Alzheimer’s pathophysiology to develop treatment and diagnosis of Alzheimer’s disease.

Increasing aging population, improved diagnostics and development of novel drugs to drive growth of the Alzheimer’s drugs market Increasing age is highest risk factor for Alzheimer’s disease, which is expected to propel demand for Alzheimer’s therapeutics. This is on account of increased life expectancy in global population, for instance according World Population Prospect report 2017, there is significant gains in life expectancy achieved globally in past decade, life expectancy at birth rose from approximately 67 to 71 years and all regions shared in the rise of life expectancy and in next several decades it would rise up to 78 years on average. As Alzheimer’s is most prevalent in age 65 year and above therefore increased life expectancy would face more patients with mild to moderate Alzheimer’s symptoms such as dementia. Europe currently has largest aged population above 60 years.

Diagnostics prospect for Alzheimer’s disease also undergoing significant development, for instance AC immune along with Piramal healthcare developing Tau-PET imaging agent for better diagnosis of Alzheimer’s disease since 2014. Current medication available for treating Alzheimer’s disease lowers the symptoms rather than targeting pathophysiology of disease, therefore market players are engaged in the development of novel drug for treatment of disease. The Alzheimer's disease market represents huge commercial potential and a successfully developed product could generate billions of dollars in revenue. For instance, Merck and Company bought an exclusive worldwide license from Japan's Teijin Pharma in 2016 to develop an investigational, preclinical anti-tau antibody, which has disease modifying potential. Genentech and AC immune are also developing anti-tau antibody, TauRx in 2017 announced phase three results of investigational drug LMTX first tau aggregation inhibitor in Alzheimer’s disease. Moreover, regulatory agencies are trying to provide accelerated approval to such drug candidate, For instance, in January 2018 FDA proposed new guidelines aimed at lowering the clinical study goals of Alzheimer's disease drugs for treating earlier-stage patients who have not yet showed functional disability or clinical abnormality, this is part of  efforts to expand access to safe and effective treatment options for many serious conditions including Alzheimer’s disease through accelerated approval for such drugs.

Browse 48 Market Data Tables and 28 Figures spread through 180 Pages and in-depth TOC on “Alzheimer’s Drugs Market”- by Drug (Donepezil, Rivastigmine, Galantamine and Memantine) by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and e-Commerce) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2025

To know the latest trends and insights prevalent in the Alzheimer’s drugs market, click the link below:

The key players are adopting strategic collaborations and acquisitions for the generating revenue from existing portfolio and a few players are collaborating for development and expansion of the product portfolio and to accelerate respective pipelines for faster delivery of the products. For instance, Teva Pharmaceutical Industries Ltd. acquired the Actavis Generics from Allergan in 2016 at around US$ 40 billion, which also includes the Alzheimer’s portfolio of Actavis Generics. This acquisition boosted revenue for Teva in its fourth quarter of 2016 and first quarter of 2017. Furthermore, companies are also undergoing strategic collaborations to develop the novel therapies for the Alzheimer’s therapeutics. For instance, Genentech and AC Immune are jointly developing anti-amyloid beta antibody crenezumab, which started phase three clinical trial in 2017. Also, they are developing anti-amyloid beta vaccine for Alzheimer’s disease treatment. Furthermore, AC immune and Janssen Pharmaceutical are also co-developing vaccine for Alzheimer’s treatment.

Key Takeaways of the Alzheimer’s Drugs Market:

  • The global Alzheimer’s drugs market is expected to exhibit a CAGR of 9.5% over the forecast period, owing to the presence of high potential market on account of aging population with increased life expectancy and rising awareness about disease in North America, Europe, and Asia Pacific.
  • Among different regions, North America holds largest share in Alzheimer’s drugs market, owing to high prevalence of Alzheimer’s disease and easy diagnosis and treatment access in region
  • Key players operating in Alzheimer’s drugs market include Pfizer, Inc., Janssen Pharmaceutical, Novartis International AG, Eisai Co. Ltd., Lundbeck A/S, and Teva Pharmaceuticals Industries Ltd


Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo